Status:
COMPLETED
Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia
Lead Sponsor:
University of California, San Diego
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
These studies look to conduct efficient pilot testing of a novel intervention strategy for chronic psychotic disorders - Pharmacologic Augmentation of Cognitive Therapy (PACT) - via an experimental me...
Detailed Description
Subjects who meet criteria for study entry come to UCSD where consenting and a comprehensive screening and diagnostic assessment including a Mini-International Neuropsychiatric Interview are conducted...
Eligibility Criteria
Inclusion
- Inclusion criteria include:
- DSM-IV diagnosis of schizophrenia or schizoaffective disorder, depressed type
- Written informed consent to participate in the study
- Age 18 - 55
- Absence of dementia or mental retardation
- Urine toxicology negative for recreational drugs
- Fluent and literate in English (needed for completion of WIN and QuickSIN)
- Exclusion criteria include:
- Meets DSM-IV criteria for current substance abuse or dependence and has been substance abstinent for less than 30 days
- A history of traumatic brain injury
- Auditory or visual impairments severe enough to prevent study participation
- Under conservatorship (determined by Anasazi)
- Pregnancy
Exclusion
Key Trial Info
Start Date :
November 9 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2024
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT04414930
Start Date
November 9 2020
End Date
December 30 2024
Last Update
December 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Teaching Facility (CTF-B102) at UCSD Medical Center
San Diego, California, United States, 92103